Impact of nirsevimab on admission to a Spanish pediatric intensive care unit because of RSV bronchiolitis: Unicentric observational study from 2017 to 2024-Reference-Cited by-同舟云学术

Impact of nirsevimab on admission to a Spanish pediatric intensive care unit because of RSV bronchiolitis: Unicentric observational study from 2017 to 2024

Published:2024-08-28 Issue: Volume: Page:
ISSN:8755-6863
Container-title:Pediatric Pulmonology
language:en
Short-container-title:Pediatric Pulmonology

Author:

Espeleta‐Fox Ana¹,García‐Salido Alberto²^ORCID,Vallespín‐Casas Almudena¹,Leoz‐Gordillo Inés¹,Unzueta‐Roch José Luis¹,De Lama Caro‐Patón Gema¹,García‐Teresa María Ángeles¹,Martínez de Azagra‐Garde Amelia¹

Affiliation:

1. Pediatric Critical Care Unit, Hospital Infantil Universitario Niño Jesús Madrid Spain

2. Pediatric Intensive Care Unit, Hospital Infantil Universitario Niño Jesús Madrid Spain

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ppul.27231

Reference6 articles.

1. Nirsevimab para la prevención de la enfermedad por virus respiratorio sincitial en niños. Posicionamiento de la Sociedad Española de Infectología Pediátrica

2. Molecular and phenotypic characteristics of RSV infections in infants during two nirsevimab randomized clinical trials

3. Early Estimate of Nirsevimab Effectiveness for Prevention of Respiratory Syncytial Virus–Associated Hospitalization Among Infants Entering Their First Respiratory Syncytial Virus Season — New Vaccine Surveillance Network, October 2023–February 2024

4. Respiratory Syncytial Virus (RSV) Burden in Infants in the Kingdom of Saudi Arabia and the Impact of All-Infant RSV Protection: A Modeling Study

5. Early estimates of nirsevimab immunoprophylaxis effectiveness against hospital admission for respiratory syncytial virus lower respiratory tract infections in infants, Spain, October 2023 to January 2024